BioSpace News Archive

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the appointment of Joseph J. Sarret, M.D., J.D. as Chief Executive Officer and Director, effective May 3, 2021.

Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise today announced that it has received the notification that its SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) is granted authorization for export.

Simulations Plus Releases ADMET Predictor ® (X.2) Industry-driven enhancements further establish ADMET Predictor® as the preferred platform for discovery PBPK simulations

BioReference Laboratories, Inc., an OPKO Health company, announced its renewal as the COVID-19 testing provider for Major League Soccer, which began on April 17 along with the 2021 MLS season.

It has been more than a year since the COVID-19 disease took the whole world by storm, and people are still getting infected. There is no doubt that the COVID-19 disease pandemic has had an unbearable and adverse impact on underserved communities with insufficient COVID-19 test access and long wait times for results

ResMed (NYSE: RMD, ASX: RMD) today announced Brett Sandercock, chief financial officer, will present virtually at the Macquarie Australia Conference on Wednesday, May 5, 2021, beginning at approximately 8:45 a.m. (Australian Eastern Standard Time) via video webcast.

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, hosted a webinar today to provide clinical updates for its first-in-class, CNS-penetrant soluble guanylate cyclase (sGC) stimulator CY6463 in Alzheimer’s Disease with Vascular pathology (ADv) and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS)

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announces it has been selected to present at the 2021 World Stem Cell Summit taking place virtually on June 14-18,

Aruvant Sciences (“Aruvant”), a private company focused on developing gene therapies for rare diseases, today announced that data on ARU-1801, a potentially curative gene therapy for sickle cell disease (SCD), will be delivered in an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

On the heels of its April 7 launch announcement, Xenter, Inc. (XenterMD.com), the world’s first start-up Device-Data-Drug healthcare technologies company, today announced that James R. Tobin has been appointed to the company’s Board of Directors.